RWD at Scale: How Verana Health and COTA Are Shaping the Future of Clinical Development

C.K. Wang and Sujay Jadhav examine how the recent Verana Health-COTA merger is accelerating the evolution of real-world data (RWD) from a retrospective insight tool into a prospective driver of clinical development strategy. With access to datasets representing 95 million patients and 25,000 providers, they discuss how machine learning is enabling more precise patient identification, improving trial feasibility, and supporting regulatory-grade evidence generation. The conversation also explores the implications for rare disease and pediatric research, as well as the growing importance of data quality, standardization, and validation in building trust across the RWD ecosystem.

In this episode, they discuss:

• How the Verana Health-COTA merger expands access to large-scale, high-quality real-world datasets
• The shift of RWD from retrospective analysis to prospective clinical trial design and execution
• The role of machine learning in patient identification, recruitment, and study feasibility
• Opportunities for advancing rare disease and pediatric research through enriched datasets
• The increasing importance of data quality, validation, and regulatory readiness in RWD use
• How RWD and traditional clinical trials can be better integrated to support decision-making
• And more!